Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Fredag 14 Mars | 14:31:29 Europe / Stockholm

Svenska | English

BioStock

BioStock: Spago takes Tumorad-01 study to the next level

2025-03-06 09:50:55

Spago Nanomedical has increased the dose of its cancer drug candidate ¹⁷⁷Lu-SN201 in its phase I/IIa Tumorad-01 study, following a recommendation from the independent Data Monitoring Committee. The decision stems from data on six patients across two cohorts with five different cancer types, all showing a satisfactory safety profile. This step keeps Spago on course to complete the phase I part in 2025.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/spago-takes-tumorad-01-study-to-the-next-level/

This is a press release from BioStock - Connecting Innovation and Capital. https://www.biostock.se/en/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden